Sanguine Corporation Announces Significant PHER-O2 Order From Virginia Commonwealth University

Published: Jul 27, 2010

PASADENA, CA--(Marketwire - July 27, 2010) - Sanguine Corporation (OTCBB: SGUI), a bio-pharmaceutical company developing products for use in biomedical and medical device applications, announces that the Company has recently received a significant order from Virginia Commonwealth University (VCU) for PHER-O2, the Company's ultra-oxygen carrying perfluorocarbon-based product. The University is considered to be one of the foremost research institutions in the United States with groundbreaking work using perfluorocarbons (PFCs). The researchers at the VCU Reanimation Engineering Shock Center (VCURES) are conducting a number of very promising pre-clinical trials, including: Neurological Events (Traumatic Brain Injury (TBI), Traumatic Spinal Cord Injury, Stroke), Organ Preservation (Cardioplegia, Heart Transplant, Liver Preservation, Kidney Transplant, Islet Cell Preservation), and Intravenous Enhanced Oxygen Delivery (Multifunctional Resuscitation Solutions, Sickle Cell Crisis, Carbon Monoxide Poisoning, Cardiopulmonary Resuscitation).

The University contracts are part of several US Federal Government funded projects underway. The University contracts amount to many millions of dollars in overall project funding. Additional projects are in various phases of the grant funding process. Sanguine will be acting as the sole supplier to these projects and will seek to participate as a partner at some point in the near future.

Mr. Frank Marra, a Company spokesperson, stated, "As a result of our approach, begun last year, to accelerate our growth through strategic and targeted development alliances, we are extremely excited about our relationship with VCU. Under Dr. Bruce Spiess' leadership, VCURES' team is considered to be at the forefront of the world's experts in research and development of innovative and novel pefluorocarbon-based solutions to a number of critical diseases and injuries. The research to be conducted with the PHER-O2 is expected to significantly advance the market acceptance of PFCs and lead to many important products and treatment methods for critical diseases and injuries."

For information related to the Sanguine Corporation, contact Investor Relations: Michael Dancy, 801-746-3570, email:

Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the Company's products, increased levels of competition for the Company, new products and technological changes, the Company's dependence on third-party suppliers, and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.

Michael Dancy
Email Contact

Back to news